GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharming Group (CHIX:PHARMa) » Definitions » EBITDA Margin %

Pharming Group (CHIX:PHARMA) EBITDA Margin % : 16.86% (As of Dec. 2024)


View and export this data going back to 2008. Start your Free Trial

What is Pharming Group EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Pharming Group's EBITDA for the three months ended in Dec. 2024 was €14.9 Mil. Pharming Group's Revenue for the three months ended in Dec. 2024 was €88.5 Mil. Therefore, Pharming Group's EBITDA margin for the quarter that ended in Dec. 2024 was 16.86%.


Pharming Group EBITDA Margin % Historical Data

The historical data trend for Pharming Group's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharming Group EBITDA Margin % Chart

Pharming Group Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
EBITDA Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 27.50 24.53 16.31 4.03 5.49

Pharming Group Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.46 -16.46 2.58 9.69 16.86

Competitive Comparison of Pharming Group's EBITDA Margin %

For the Biotechnology subindustry, Pharming Group's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pharming Group's EBITDA Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pharming Group's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Pharming Group's EBITDA Margin % falls into.


;
;

Pharming Group EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Pharming Group's EBITDA Margin % for the fiscal year that ended in Dec. 2024 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2024 )/Revenue (A: Dec. 2024 )
=15.581/283.826
=5.49 %

Pharming Group's EBITDA Margin % for the quarter that ended in Dec. 2024 is calculated as

EBITDA Margin %=EBITDA (Q: Dec. 2024 )/Revenue (Q: Dec. 2024 )
=14.923/88.502
=16.86 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Pharming Group  (CHIX:PHARMa) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.


Pharming Group EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of Pharming Group's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Pharming Group Business Description

Address
Darwinweg 24, Leiden, ZH, NLD, 2333 CR
Pharming Group is a biopharmaceutical company. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome. In addition, the firm's development pipeline includes KL1333, a potential first-in-disease asset for mitochondrial DNA-driven primary mitochondrial diseases. The company's reportable segments are RUCONEST, which derives maximum revenue, Joenja, U.S., and Europe and the Rest of the World (RoW). Geographically, it derives maximum revenue from the United States.

Pharming Group Headlines

No Headlines